© 2026 CellCarta - All rights reserved.
CellCarta’s genomics services offer precise biomarker data, without wasting time, tissue or budget. Our team helps biopharma programs choose the right assays for their needs, from focused PCR to targeted NGS panels, through to WES, RNASeq and WGS.
Get the data your program needs, while reducing workflow fragmentation, handoffs, and patient management friction.
"Your RNASeq services are best in class and delivered lower duplication rates and much better unique read coverage…"
Use PCR workflows when known biomarkers need fast, actionable answers for patient management.
From single genes to the Biofidelity Aspyre® Lung assay, which provides NSCLC screening across 11 genes in tissue or blood with minimal input and a rapid turnaround.
Start focused when speed matters, expand to targeted NGS when you need insights into a range of actionable genomic alterations (AGAs), and go deeper into comprehensive DNA and RNA profiling when broader biology matters.
Clinical Trials Supported
470+
Focused PCR
Use PCR workflows when known biomarkers need fast, actionable answers for patient management. From single genes to the Biofidelity Aspyre® Lung assay, which provides NSCLC screening across 11 genes in tissue or blood with minimal input and a rapid turnaround.
Clinical Trials Supported
NGS panels provide just the data you need, whether you're looking for specific mutations or wider panels of tumor biomarkers.
Whether 22 genes or panel of >500 genes is a better fit, targeted NGS is the answer when full sequencing would add unnecessary depth, cost, or complexity.
When the biology demands deeper insight, CellCarta provides WES, RNA-seq and WGS, without changing partners. These comprehensive sequencing options deliver high-quality in-depth data, for when you need a full picture.
For therapies that need human leukocyte antigen (HLA) typing for patient management, we determine HLA type (HLA-A, -B, -C, DRB1, DQB1 & DPB1) with greater accuracy than Sanger sequencing, in a NGS assay validated for clinical use.
CellCarta elevates existing RUO and in-house assays (CTAs) into robust clinical trial assays for patient management. Plus, our in-house biobank can accelerate timelines with rapid access to more than 4,000 phenotype-characterized samples.
Histopathology, tissue genomics, liquid biopsy, and HLA typing, all in one operational model. CellCarta's comprehensive laboratory services enable your patient management pipeline with fewer handoffs, for faster actionable answers.
Validated Assays
60+
Assay Development Projects
100+
CDx Projects Supported
30+
CellCarta connects histopathology, IHC/IF, tissue genomics, liquid biopsy analysis, and HLA typing in one operational model.
When you need a partner to support therapeutic development and patient management, we offer comprehensive genomic laboratory services, with comprehensive multi-modal biomarker support. With validated assays and globally standardized execution across North America, Europe, and China, we're ready, wherever your trial takes you.
The result is fewer handoffs, better tissue optimization, and faster patient management decisions across the full biomarker continuum.
Start focused when speed matters, expand to targeted NGS when you need insights into a range of actionable genomic alterations (AGAs), and go deeper into comprehensive DNA and RNA profiling when broader biology matters.
NGS panels provide just the data you need, whether you're looking for specific mutations or wider panels for tumor biomarkers.
Whether 22 genes or panel of >500 genes is a better fit, targeted NGS is the answer when full sequencing would add unnecessary depth, cost, or complexity.
When the biology demands deeper insight, CellCarta provides WES, RNA-seq and WGS, without changing partners. These comprehensive sequencing options deliver high-quality in-depth data, for when you need a full picture.
For therapies that need human leukocyte antigen (HLA) typing for patient management, we determine HLA type (HLA-A, -B, -C, DRB1, -DQB1 & DPB1) with greater accuracy than Sanger sequencing, in a NGS assay validated for clinical use.
CellCarta elevates existing RUO and in-house assays (CTAs) into robust clinical trial assays for patient management. Plus, our in-house biobank can accelerate timelines with rapid access to more than 4,000 phenotype-characterized samples.
Histopathology, tissue genomics, liquid biopsy, and HLA typing, all in one operational model. CellCarta's comprehensive laboratory services enable your patient management pipeline with fewer handoffs, for faster actionable answers.
CellCarta connects histopathology, IHC/IF, tissue genomics, liquid biopsy analysis, and HLA typing in one operational model.
When you need a partner to support therapeutic development and patient management, we offer comprehensive genomic laboratory services, with comprehensive multi-modal biomarker support. With validated assays and globally standardized execution across North America, Europe, and China, we're ready, wherever your trial takes you.
The result is fewer handoffs, better tissue optimization, and faster patient management decisions across the full biomarker continuum.
Validated Assays
Assay Development Projects
CDx Projects Supported
PBMC Processing
Same-day PBMC processing following robust SOPs across labs in NA, EU, Australia, and China.
PBMC Processing
Same-day PBMC processing following robust SOPs across labs in NA, EU, Australia, and China.
Lead Outsourcing Director, Biopharma
Biopharma Partner
Lead Outsourcing Director, Biopharma
“CellCarta was able to present a proposal in less than a week and they were ready to contract to get kits to our sites as soon as possible. They offered expedited start up without breaking the bank on costs to get the database and lab manual ready for review and sign off faster than any other central lab I've come across.”
Lead Outsourcing Director, Biopharma
“CellCarta was extremely helpful with the data analysis: great shout out to the data analysis team! The team in MTL was super fast and super professional!”
Biopharma Partner
"CellCarta’s project managers are supportive and attentive — they coordinate with your data team, CRO/CRAs, and other vendors as needed. They don't wait for us as the sponsor to bring issues up; they bring concerns to our attention and come prepared with resolution options.”
Lead Outsourcing Director, Biopharma